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ABSTRACT 
Purpose: To assess the clinical value of reporting full-field electroretinogram (eg, flicker ERG) findings 
graphically to determine the severity of diabetic retinopathy (DR) within an office-based setting. 
Methods: Patients with type 2 diabetes mellitus were included and classified into varying degrees of DR 
based on presence and severity. Flicker ERG responses were recorded and compared between groups. 
Results: Between the varying disease stages, significant differences in the mean magnitude and phase 
values were found. There was also a significant difference between the proportions of the magnitude 
and phase color-coded frequencies between groups of severity and threat to vision. 
Conclusion: Magnitude and phase parameters of the flicker ERG test may be used to stage disease 
severity in patients with ongoing DR and determine risk of worsening. With utilization of these values 
organized into a visual diagram, interpretation of the recording may be more efficient and facilitate 
appropriate management of DR within the primary care setting. 
 
INTRODUCTION 
As the leading cause of blindness in the world [1], diabetic retinopathy (DR) is one of the most 
commonly managed diseases in the day-to-day operations of many clinical settings. The mainstay 
method in prevention involves optimal metabolic control that can reduce the risk of DR progression in 
diabetic patients. These parameters have been defined as maintaining HbA1c, blood pressure, and low-
density lipoproteins levels below 7%, 130/85 mmHg, and 100 mg/dl, respectively [1,2]. Once sight-
threatening DR is detected, treatment options are available but limited. Laser photocoagulation and 
vitrectomy are standard interventions in disease management protocol, however, both carry additional 
risks of vision loss and neither has been shown to be effective at reversing vision loss incurred by the 
disease [2,3]. Within recent years, intravitreal anti-vascular endothelial growth factor (anti-VEGF) 
therapy has shown to be a safer therapeutic alternative for the treatment of proliferative DR (PDR) and 
is often used in conjunction with the aforementioned interventions. While these injections have been 
shown by several clinical trials to effectively improve vision in patients with diabetic macular edema 
(DME), a common complication of DR [4,5], they are not effective in a large proportion of the population 
for treating the underlying disease process. Of patients with PDR at baseline, 40% of patients receiving 
laser treatment alone, 21% of patients treated with anti-VEGF injections (ranibizumab) combined with 
prompt laser therapy, and 18% in patients treated with anti-VEGF (ranibizumab) with deferred laser 
treatment showed worsening of retinopathy after three years [3]. Several factors account for these 
differences and may be attributed to standardized treatment guidelines, which often consist of 
regimented schedules for intravitreal injections requiring close follow-up and strict compliance for 
efficiency. Thus, the essentials for best outcomes in managing DR include early detection and prevention 
through strict glycemic control and close follow-up-- which are, unfortunately, not always easily 
achieved, particularly in developing nations [1,5]. 
With the advent of imaging modalities utilized for retinal diseases, several diagnostic techniques 
have been used as guides for detecting disease progression in the eye, as well as response to treatment. 
Today, conventional screening includes clinical examinations by ophthalmoscopy, fluorescein 
angiography (FA), and optical coherence tomography (OCT). The gold standard in diagnosing DR is with 
stereoscopic color fundus photography in 7-standard fields [2]. With the exception of OCT, these 
methods require subjective and qualitative assessments with skilled analysts and, particularly with the 
gold standard, can be uncomfortable and time-consuming [6]. Increasing utilization of OCT for detecting 
changes in retinal thickness has made it a prominent tool for following DR and DME. It provides both 
objective and quantitative measures useful for staging the disease based on the structural components 
within the posterior pole of the retina [2,5]. The development of imaging studies applied to DR have 
provided a wealth of evidence to explain the anatomical changes observed late within the disease 
process, such as microvascular abnormalities and intra-retinal swelling. However, these changes are only 
clinically apparent once visibly detected and existing diagnostic modalities are limited in value for 
detecting functional changes before appearance of structural abnormalities. Therefore, routine testing is 
most helpful once the patient starts to notice a decline in visual function, or under circumstances of 
vision-threatening DR (VTDR) warranting prompt treatment intervention. Despite technological 
advancements, there is yet to be established a test that accurately serves as a measure of retinal 
function in predicting the onset of retinopathy before DR manifests clinically [5,6]. Furthermore, such a 
test has yet to be implemented in the common clinical setting of managing DR. 
Flicker ERG is relatively well-known among practicing ophthalmologists as a test for retinal layer 
function [1,6]. Like the OCT, it can be analyzed objectively and quantitatively. Through a review of the 
existing literature, we found that flicker ERG establishes its role as a tool for measuring global retinal 
function. Several studies have demonstrated the efficacy of ERG for the early detection of retinal 
dysfunction when screening diabetic patients [1,6]. However, there is often little discussion regarding 
the implementation of flicker ERG into everyday clinical practice. Conventional ERG methods would 
previously involve large, bulky equipment and lengthy preparation, causing inconveniences and delays 
within the confined exam rooms of a fast-paced clinic [1,6]. These issues have largely been resolved by 
refined, non-mydriatic recording devices that take significantly less time to operate. The Neuro Optic 
Vision Assessment (NOVA)™ ERG system (Diopsys Inc., Pine Brook, NJ, USA) comes equipped with a 
handheld dome and disposable skin electrodes that are placed on the outer aspect of the lower eyelids. 
The compact size and minimal operation time predicate its role for the mass-screening of retinal 
diseases, not only in specialty ophthalmology clinics but also generalist and primary care practices.  
The purpose of the present study was to examine components of the flicker ERG in diabetic 
patients with ocular involvement of varying severities. Our goal is to highlight the usefulness of 
graphically analyzing flicker ERG as a means to stage between nonproliferative diabetic retinopathy 
(NPDR) and PDR, as well as VTDR, from the generalist standpoint. Thus, we aim to establish the clinical 
value of assessing retinal dysfunction in DR patients through values of NOVA™ flicker ERG parameters 




This study is a retrospective, observational, single-center analysis conducted in accordance with 
the Declaration of Helsinki and is HIPAA compliant. All patients gave their written informed consent 
prior to being included in the study.  
The electronic charts of all patients undergoing routine clinical examinations at the Valley Retina 
Institute (McAllen, TX, USA) who had received a baseline flicker ERG from the period January 2018 to 
November 2020 were examined. Of these patients, those who were clinically diagnosed with type 2 
diabetes mellitus (T2DM) were included and were classified by severity of DR into five groups: no DR, 
mild NPDR, moderate NPDR, severe NPDR, and PDR. The diagnosis of T2DM was established according 
to the diagnostic criteria of the American Diabetes Association (ADA). The diagnosis and classification of 
DR was established according to the International Clinical Diabetic Retinopathy and Diabetic Macular 
Edema Disease Severity Scales [7]. Patients were secondarily separated by the presence of VTDR, which 
was defined as having a diagnosis of either severe NPDR or PDR. 
All patients had undergone a comprehensive ophthalmologic examination, including review of 
medical records, best corrected visual acuity (BCVA), intraocular pressure measurement, slit-lamp 
biomicroscopy, and indirect ophthalmoscopy with a 20-diopter lens. Retinal function was tested with 
the NOVA™ flicker ERG system. Age, gender, and race of each patient were recorded. Patients were 
excluded if they had a history of epilepsy, were unable to tolerate the exam, or if their flicker ERG 
recordings indicated poor signal quality of response in either eye. A historical control group was used to 
compare flicker ERG parameters between DR patients and normal controls [8]. 
 
Full-field flicker ERG examination 
 Flicker ERG was performed with the in-office NOVA™ ERG system in an illuminated room free of 
visual distractions. Patients were not dilated and were seated in front of the device monitor at a 
distance of about 24 inches. The skin on the lower eyelids was cleansed with lid scrub pads (OCuSOFT®, 
Inc., Richmond, TX, USA) and the skin on the center of the forehead was prepped with Nuprep™gel 
(Weaver and Co., Aurora, CO, USA). Disposable, adhesive ERG skin electrodes were positioned on the 
lower lid of each eye and a disposable electroencephalogram (EEG) electrode was secured to the center 
of the forehead with Ten20 conductive paste (Weaver and Co., Aurora, CO, USA) as a ground electrode. 
Patients were asked to hold the mini-Ganzfeld dome over the testing eye while focusing on a target 
displayed on the device monitor with the fellow eye. The testing eye was simulated by 3 cd*s/m2 light 
flashes flickering at a frequency of 32 Hz over a white background of 30 cd/m2 within the handheld 
dome. The stimulus was presented over a total duration of 20 seconds per eye. The test protocols meet 
the standard of the International Society of Clinical Electrophysiology of Vision (ISCEV). An age-adjusted 
normative database provided by the manufacturer for identical testing parameters aided the study 
interpretation by color-coded reference ranges. 
 
Statistical analysis 
 Demographic data is summarized as means and standard deviations (SDs) or percentages when 
appropriate. Flicker ERG parameters of magnitude and phase values are reported numerically, as well as 
categorically based on color-coded reference ranges. Two-tailed unpaired t-tests were performed for 
comparisons between DR patients and historical controls, as well as between those with and without 
VTDR. A one-way analysis of variance (ANOVA) was performed to compare means of magnitude and 
phase between the five groups of varying DR severity. Similarly, categorical variables were compared 
between groups with a Chi-squared test. Normality of data distribution was tested by Q-Q plot. The level 
of significance was set at P ≤ 0.05. All statistical analysis was performed with R Statistical Software, 
version 1.3.1073 (R Foundation for Statistical Computing, Vienna, Austria). 
 
RESULTS 
259 eyes of 130 patients were identified and included in this study (60 males and 70 females). 
The mean ages of DR patients and historical healthy controls were 66.2 ± 10.9 years (range 31-92) and 
53.3 ± 16.6 years (range 21-81), respectively. There was no significant difference in age between all 
groups included in our study (P=0.054). The age difference between our DR patients and the historical 
control group was statistically significant (P<0.0001). The majority of DR patients identified as Hispanic 
or Latino (71%) whereas the majority of the control group were reported as Asian (38%). Demographic 
data is shown in Table 1.  
The mean magnitude and phase values were compared between the patients included in our 
study and normal controls (Table 2). The average flicker ERG magnitude of all DR patients was 7.87 ± 4.8 
µV (range 0.06-21.26) and for the control group it was 10.14 ± 3.52 µV. The average flicker ERG phase 
value of all DR patients was 264.92 ± 50.69 degrees and for the control group it was 305.24 ± 25.55 
degrees. Both magnitude and phase averages were both found to be significantly different between our 
patients and normal controls (P=0.0022). 
A flicker ERG recorded from a normal control is shown in Figure 1. Figure 2 shows flicker ERGs 
recorded from four representative subjects from our study, each with a different degree of DR: mild 
NPDR, moderate NPDR, severe NPDR, and PDR. Along with reported numerical values, measures of 
magnitude and phase are organized into a circular graph, called the “Mag/Phase Plot”, of which certain 
regions are demarcated by different colors. The margins depicted as green, yellow, and red indicate 
retinal function as normal, mild dysfunction, or severe dysfunction, respectively. These color-coded 
references were used along with the corresponding numerical values of flicker ERG magnitude and 
phase to assess retinal function between the five groups in this study. 
All of the 259 eyes were divided into five groups: no DR (n=6), mild NPDR (n=78), moderate 
NPDR (n=52), severe NPDR (n=16), and PDR (n=107). The mean magnitude and phase values of the five 
groups were compared (Table 3). The results indicated significant differences in both the magnitude and 
phase values between the groups. Furthermore, when comparing proportions of magnitude and phase 
values based on the color-coded reference ranges between the groups, significant differences were 
found in both parameters (P<0.0001). 
In order to divide subjects into groups with or without VTDR, we further classified patients with 
no DR, mild NPDR, and moderate NPDR into a “non-VTDR” group (n=136) and those with severe NPDR 
and PDR into a “VTDR” group (n=123). The data is demonstrated in Table 4. There were significant 




TABLES AND FIGURES 
 
 Our Study Controls 
No. of Patients (N) 130 50 
Age (mean ± SD) 66.2 ± 10.9 53.3 ± 16.6 
Gender (male/female) 60/70 22/28 
Race (% of N)   
Hispanic or Latino 71% 0% 
Asian 0% 38% 
Caucasian 9% 32% 
African American 0% 18% 
Other* 20% 12% 
Table 1. Demographic data of patients included in our study and historical control group. 









Magnitude (µV) 7.87 ± 4.8 (0.06-21.26) 10.14 ± 3.52 (9.11-11.17) 0.0022* 
Phase (o) 264.92 ± 50.69 (103.13-
448.69) 
305.24 ± 25.55 (297.74-
312.74) <0.0001* 
Table 2. Mean flicker ERG magnitude and phase values compared between our patients and historical 
control group. 




Figure 1. A representative flicker ERG recording of a pair of normal eyes. The right eye is depicted on the 
left (OD) and the left eye is depicted on the right (OS). Response signals of each eye are recorded in 
parameters of magnitude and phase and are organized qualitatively into a Mag/Phase Plot with the 
according quantitative values highlighted by color of the appropriate reference range. 
 
Figure 2. Representative flicker ERGs recorded from four subjects with various severities of DR, including 
mild NPDR (A), moderate NPDR (B), severe NPDR (C), and PDR (D). Increasing degree of severity of DR 
corresponds to changes in magnitude and phase values based on appearance and position on 
Mag/Phase plot and color references. 
 
 










Magnitude (µV) 7.34 ± 1.87 9.58 ± 4.01 10.87 ± 5.64 6.95 ± 2.95 5.4 ± 3.88 <0.0001* 
Green 6 68 41 13 47 ** 
Yellow 0 6 7 1 24 ** 
Red 0 4 4 2 36 ** 
Phase (o) 304.37 ± 19.2 267.87 ± 53.93 277.08 ± 42.32 254.99 ± 28.7 256.37 ± 53.65 0.0324* 
Green 6 59 32 5 37 ** 
Yellow 0 6 6 3 10 ** 
Red 0 13 14 8 60 ** 
Table 3. Parameters of flicker ERG test in different groups of DR. 
*Data is described as [mean ± SD] and analyzed with one-way ANOVA. 







Magnitude (µV) 9.96 ± 4.68 5.6 ± 3.8 <0.0001* 
Green 115 60 ** 
Yellow 13 25 ** 
Red 8 38 ** 
Phase (o) 272.94 ± 49.23 256.19 ± 51.01 0.0072* 
Green 97 42 ** 
Yellow 12 13 ** 
Red 27 68 ** 
Table 4. Parameters of flicker ERG test in groups of non-VTDR and VTDR. 
*Data is described as [mean ± SD] and analyzed with two-tailed t-test. 
**Data described as observed counts and analyzed with Chi-squared test with all p-values <0.0001. 
 
DISCUSSION 
In our study, we assess the clinical value of interpreting both magnitude and phase parameters 
of the flicker ERG test by color as compared between groups of varying degrees of DR, from none to 
proliferative. We also evaluated the ability of the test to discriminate for VTDR. These parameters were 
reported with quantitative measures, as well as qualitative measures by depiction through a simple 
graph, the Mag/Phase Plot. Both measures were associated with color-coded reference ranges supplied 
by the database of the Diopsys device and were used to assess differences between groups of DR 
patients. Our results report significant differences of the means and color proportions of the magnitude 
and phase values between the DR groups, as well as between those with and without VTDR. These 
findings suggest that the flicker ERG test serves as a promising tool for following disease progression of 
DR and to guide treatment. 
One interesting finding seen in the present study was the relatively large magnitude and phase 
flicker ERGs in eyes with moderate NPDR (Table 3). It is thought that altered retinal hemodynamics in 
diabetic individuals would be unable to maintain sufficient perfusion in response to a rapid flicker of 
light, thereby attenuating the response to flicker ERG testing [9-11]. Changes in different ERG 
components can also occur depending on various factors, such as glucose load and pupillary size [12,13]. 
Instances of supernormal flicker ERG parameters in diabetic eyes have been attributed to transduction 
abnormalities, neuronal activity, and photoreceptor sensitivity loss [6,10], findings that are often 
present during stages of active disease progression. Given that our threshold cutoff for VTDR was met 
for any condition worse than moderate NPDR, this may explain the higher flicker ERG values within this 
group, though these speculations have not been overtly established. Additionally, since our exclusion 
criteria was limited to maximize the sample size, these values may have been influenced by confounding 
factors, such as history of intravitreal injections, ocular surgery, laser therapy, and more. 
There are a handful of studies that report the feasibility of the flicker ERG test in screening for 
DR among diabetic patients [1,6,11]. Our findings corroborate these reports, but we also establish a 
novel method of assessment. Previous studies established their conclusions based on the recorded 
flicker ERG parameters reported numerically [6,11], whereas we also incorporated their references 
based on color. By doing so, the time to mentally translate “text” to “numbers” to “associated level of 
severity” is reduced. Presumably, linking the colors of green, yellow, and red to three broad 
classifications (i.e., good, okay, bad) allows a much simpler thought process and eliminates the need to 
memorize or look up criteria guides for certain disease stages. 
To the best of our knowledge, no one has introduced flicker ERG responses organized into a 
Mag/Phase Plot as an easy modality for the swift diagnosis of retinal diseases. The Mag/Phase plot 
records retinal signals as lines in response to each flash stimulus during the flicker test; it incorporates 
the amount of the response (i.e., magnitude; depicted by length of line), speed of response (i.e., phase; 
denoted by where in the circle the line lies), and reproducibility (i.e., reliability; determined by inverse 
association to separation of lines from each other). The magnitude of the signal reflects the function of 
cone cells, which are anatomically distributed throughout the retina, and the phase is a measure of the 
timing of the response. The variance of these measurements represents the consistency of the strength 
and speed of the signal. Together, these parameters provide a straightforward analysis of retinal 
function that may be successfully and efficiently interpreted by clinicians from all backgrounds. By 
understanding green as “good”, yellow as “okay”, and red as “bad”, the Mag/Phase Plot can be 
evaluated by the general practitioner to the comprehensive ophthalmologist and beyond.  
As seen in our representative sample of patients with DR (Fig. 2), conditions in which the degree 
of severity is stable within the mild-to-moderate range of DR will have flicker ERG readings mostly in the 
“green”, where the plot points lie within the lower right quadrant of the graph. In contrast to those 
ranging in severe NPDR-to-PDR stages, the plot points may make their way closer toward the lower left 
quadrant zoned with yellow and red color references, which indicate a more drastic underlying disease 
process. It is important to know, however, that other pre-existing conditions or treatments may alter the 
retinal response. For example, consider two individuals each diagnosed with moderate NPDR, where 
one has never received any medical or surgical treatment and the other maintains routinely scheduled 
appointments for anti-VEGF injections. The flicker ERG of the treatment-naive individual may illustrate a 
more complex disease picture warranting timely intervention compared to that of the treated patient, 
whose report may appear to suggest either a stable or improving condition. While flicker ERG alone may 
not always be the best initial tool to diagnose and stage DR, its value in establishing baseline readings 
and monitoring for progression during follow-up periods is clear. Furthermore, with improvements in 
the diagnostic preparation time and portability, flicker ERG may be deployed in smaller spaces and 
rapidly moving environments. 
Our study herein illustrates the applicability of the Mag/Phase Plot to a fast-paced clinical 
setting. However, there are several limitations to consider. First, our study was limited by the nature of 
its retrospective design. Another limitation was our small sample size. This has been consistent with 
prior studies [1,6,11] and bears need for prospective studies with a larger number of participants. Third, 
as we were unable to locate flicker ERG studies performed on normal or healthy patients seen by the 
clinic, we compared our study patients to a historical control group that did not appropriately match up 
by demographic characteristics. Furthermore, we were unable to find existing data regarding evaluation 
of retinal function as determined by the Mag/Phase Plot, and so no controls were examined for 
comparison. Considering our limited exclusion criteria, we did not appropriately account for associated 
or underlying issues, such as diabetic cataracts or glaucoma, which may have influenced our findings. 
Therefore, a control group would have been especially helpful to determine differences between our 
patients.  
In conclusion, we found that the flicker ERG test interpreted by color can be used as a tool to 
evaluate for disease severity among patients with T2DM, DR, and VTDR. While the reason why eyes with 
moderate NPDR tended to have larger magnitude and phase values was not determined, it had no 
apparent effect on the analysis of flicker ERG reports based on color-coded references. Future directions 
include addressing the aforementioned limitations and further studies to provide more accurate results 
of significant differences, as well as determine the detection performance, sensitivity and specificity of 
the flicker ERGs to discriminate DR stages and VTDR. 
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